Roflumilast

The evidence splits sharply by use. Approved COPD use rests on large replicated phase III trials and a Cochrane review of roughly 18,000 patients, showing a real but modest anti-inflammatory benefit (a small FEV1 gain and fewer exacerbations) alongside genuine GI and psychiatric side effects. Topical dermatology use is backed by positive vehicle-controlled phase III trials. The cognitive or nootropic claim is the exciting frontier but the weakest evidence: a handful of small human studies from two research groups report improved verbal and episodic (not working) memory at sub-emetic doses of 100-250 micrograms, with small-to-moderate effect sizes. The largest chronic low-dose trial (post-stroke, n=100) was negative on its primary analysis and significant only after post-hoc adjustment, and a dedicated MCI/Alzheimer's trial remains unreported. Robust rodent data show roflumilast lifts hippocampal cAMP, CREB, and BDNF and improves memory at doses far below the emetic threshold, but rodent-to-human nootropic translation has historically been weak. Bottom line: approved and effective as a modest anti-inflammatory; promising but unestablished as a cognitive enhancer.

Prescription medicine. At the approved 500 microgram COPD dose the common effects are gastrointestinal and metabolic: diarrhea (roughly three times more likely than placebo), nausea, reduced appetite and weight loss of about 2 kg, headache, insomnia, and dizziness, with more treatment withdrawals than placebo. The FDA label carries a psychiatric warning covering insomnia, anxiety, depression, and suicidal ideation or behavior, so it should be used cautiously by anyone with a mood-disorder history and weight should be monitored.

It is contraindicated in moderate-to-severe hepatic impairment (Child-Pugh B or C) and is not for acute bronchospasm; exposure rises with strong CYP3A4/1A2 inhibitors. At the 100-250 microgram cognition doses, short-term human side effects have been close to placebo, but those data are only single-dose to roughly eight days, so chronic low-dose safety is genuinely unestablished and the warnings derived from chronic dosing cannot be dismissed. The topical form (Zoryve) largely avoids systemic effects, causing mostly application-site reactions.

Roflumilast is metabolized primarily by CYP3A4 and CYP1A2, making it susceptible to drug interactions with both inhibitors and inducers of these enzymes ^[8]. Strong CYP3A4 inhibitors such as ketoconazole and itraconazole decrease roflumilast clearance substantially ^[8]. Weaker inhibitors like cimetidine cause increases of approximately 47% in roflumilast PDE4 inhibitory activity ^[9], while enoxacin (a potent CYP1A2 inhibitor) causes a 25% increase ^[10]. This is a pharmacokinetic interaction where the inhibitor raises roflumilast levels. Strong CYP3A4 inducers such as rifampicin reduce roflumilast exposure substantially and should be avoided; alternatively, roflumilast dose reduction is recommended with strong inhibitors ^[8]. The dual CYP3A4/CYP1A2 inhibitor fluvoxamine also requires caution or dose reduction.

Roflumilast can be co-administered with many medications used in COPD (including bronchodilators and corticosteroids) without clinically significant interaction. However, documentation of interactions with other commonly used medications, beyond CYP enzyme perpetrators, remains limited in the literature.

Checking a whole stack? Run it through interactions + stacks.

Roflumilast was the first selective PDE4 inhibitor approved for COPD, emerging from a lineage of Byk Gulden and Altana research that passed through Nycomed to Takeda. It was approved in Europe as Daxas in 2010 and in the United States as Daliresp by the FDA in 2011 for reducing exacerbations in severe COPD with chronic bronchitis, and is now generic. In 2022 Arcutis won the first FDA approval for a topical formulation, Zoryve, for plaque psoriasis, later expanding to atopic and seborrheic dermatitis. Its use as a cognitive enhancer is entirely investigational and off-label, driven by academic groups at Maastricht and King's College London exploring the drug's unusually wide memory-versus-emesis window.

Among respiratory physicians roflumilast is regarded as a niche add-on, reserved for the specific severe-COPD, chronic-bronchitis, frequent-exacerbator patient rather than a first-line drug, prized for a real but modest benefit that comes with notable GI and psychiatric caveats. In biohacking and nootropic circles it has developed a very different reputation as a rare PDE4 inhibitor that appears to sharpen verbal memory at microscopic, sub-emetic doses, prompting interest in splitting the cheap generic tablet. The honest framing is that this enthusiasm runs ahead of the data: the human cognitive evidence is small, mixed, and mostly short-term, the one large chronic trial missed its primary endpoint, and no one has established what daily low-dose use does over months or years.